Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Syndax Pharmaceuticals (SNDX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Syndax Pharmaceuticals's actual EPS was -$1.10, missing the estimate of -$0.23 per share, resulting in a -370.69% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
